Skip to main content
. 2016 Aug 11;7(37):60310–60331. doi: 10.18632/oncotarget.11203

Figure 7. Wnt signalling is also a bi-directional vulnerability in malignant melanoma and colorectal cancer cells.

Figure 7

(A) Cell viability analysis of the dose response of a panel of malignant melanoma cell lines treated for 48 h with ICG-001 or Wnt agonist 1, as detected by MTS assay. (B) Cell viability analysis of the dose response of colorectal cancer cell lines (HCT116 and HT29) treated for 48 h with ICG-001 or Wnt agonist 1, as detected by MTS assay. (C) Imaging of HCT116 cells treated for 24 h with Wnt inhibitor, ICG-001 or Wnt activator, Wnt agonist 1. All panels are imaged at 40x magnification.